Compare CADL & BGH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CADL | BGH |
|---|---|---|
| Founded | 1999 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 278.7M |
| IPO Year | 2021 | 2011 |
| Metric | CADL | BGH |
|---|---|---|
| Price | $11.94 | $13.53 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $19.00 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 67.5K |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.06% |
| EPS Growth | ★ 58.62 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $125,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.35 | $13.19 |
| 52 Week High | $14.00 | $16.65 |
| Indicator | CADL | BGH |
|---|---|---|
| Relative Strength Index (RSI) | 48.82 | 31.10 |
| Support Level | $9.40 | N/A |
| Resistance Level | $14.00 | $14.35 |
| Average True Range (ATR) | 0.71 | 0.14 |
| MACD | -0.18 | -0.04 |
| Stochastic Oscillator | 46.56 | 3.87 |
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Barings Global Short Duration High Yield Fund is a diversified, closed-end management investment company. Its investment objective is to seek as high a level of current income as the Adviser determines is consistent with capital preservation. The Fund seeks capital appreciation as a secondary investment objective when consistent with its primary investment objective. Under normal market conditions, the Fund will invest at least 80% of its Managed Assets in bonds, loans and other income-producing instruments that are, at the time of purchase, rated below investment grade.